The partnership will bring Royal Biologics’ products to more patients in the U.S., including the Fibrinet platelet rich fibrin matrix for spinal fusions and the Maxx-PRP for orthopedics.
The partnership will also seek adoption of the biologics in the VA and department of defense.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
